What We're Reading
Industry reads hand-picked by our editors
May 03, 2024
-
Fierce Pharma
WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions
-
NPR
Could the U.S. produce an effective bird flu vaccine for humans, if needed?
-
Healthcare Dive
Walgreens inks GLP-1 clinical trial deal with major German drugmaker
-
JAMA
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
May 02, 2024
May 01, 2024
Apr 30, 2024
-
STAT
Federal judge rules against two drugmakers challenging Medicare drug price negotiation program
-
Fierce Biotech
Novartis pays PeptiDream $180M as radiopharma big bang continues
-
The Boston Globe
FDA approves X4 Pharmaceuticals’ drug for ultra-rare WHIM syndrome
-
The Pharma Letter
Amgen deal frees Sandoz to launch Prolia and Xgeva biosimilars next year
Apr 29, 2024
-
Stat
MorphoSys faces serious safety risk related to cancer drug, pelabresib
-
The Washington Post
Ecstasy’s bid for FDA approval reveals challenges of psychedelic trials
-
Axios
Steep Ozempic, Wegovy prices face fresh scrutiny from officials
-
The Wall Street Journal
Star Scientist’s Claim of ‘Reverse Aging’ Draws Hail of Criticism
Apr 26, 2024
-
Financial Times
Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma
-
Reuters
Bayer investor Deka takes a stand against CEO in annual vote
-
LifeSciVC
The Biotech Startup Contraction Continues... And That’s A Good Thing
-
MedTech Dive
Freenome to cut more than 100 employees in restructuring
Apr 25, 2024
-
Reuters
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
-
CNBC
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
-
The Wall Street Journal
McKinsey Under Criminal Investigation Over Opioid-Related Consulting
-
The Economist
Many mental health conditions have bodily triggers